NEW YORK (GenomeWeb) – Laboratory Corporation of America said today that its pending acquisition of Sequenom has passed antitrust review.

Expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 satisfies one of the conditions needed to complete the acquisition.

In July, LabCorp said it planned to acquire Sequenom for $302 million in cash, or $2.40 per share, in a deal it expected to close by the end of the year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.